Edition:
United Kingdom

Edge Therapeutics Inc (EDGE.OQ)

EDGE.OQ on NASDAQ Stock Exchange Global Select Market

13.95USD
16 Feb 2018
Change (% chg)

$0.05 (+0.36%)
Prev Close
$13.90
Open
$13.84
Day's High
$14.12
Day's Low
$13.84
Volume
17,256
Avg. Vol
23,537
52-wk High
$14.40
52-wk Low
$7.44

Latest Key Developments (Source: Significant Developments)

Edge Therapeutics Says EG-1962 Phase 3 Study Continues As Planned Following Completion Of Futility Analysis
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Edge Therapeutics Inc ::EDGE'S EG-1962 PHASE 3 NEWTON 2 STUDY CONTINUES AS PLANNED FOLLOWING COMPLETION OF FUTILITY ANALYSIS.EDGE THERAPEUTICS - INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDED PHASE 3 NEWTON 2 STUDY OF EG-1962 CONTINUE AS PLANNED.  Full Article

Edge Therapeutics reports qtrly loss per share $‍0.37​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Edge Therapeutics Inc :Edge Therapeutics reports third quarter 2017 financial results.Edge Therapeutics Inc - qtrly loss per share $‍0.37​.  Full Article

Edge Therapeutics reports Q2 loss per share $0.33
Wednesday, 3 Aug 2016 

Edge Therapeutics Inc :Quarterly loss per share $0.33.  Full Article

Edge Therapeutics says received FDA fast-track designation for drug to treat subarachnoid hemorrhage
Friday, 13 May 2016 

Edge Therapeutics Inc : Expects to begin enrollment in mid-2016, a pivotal phase 3 multi-center, multi-national, randomized, double-blind, placebo-controlled, parallel-group study .Edge Therapeutics receives FDA fast track designation for Eg-1962 for the treatment of subarachnoid hemorrhage.  Full Article